Motion Sickness Drugs Market Size to grow by USD 139.5 million between 2024-2028

Technavio, a leading provider of market research reports, has released its latest study on Motion Sickness Drugs Market. This report offers a comprehensive analysis of the current market trends, emerging opportunities, and key challenges.

Key Highlights:

• Market Research Overview: The Motion Sickness Drugs market is a significant segment of the larger global pharmaceuticals industry, encompassing entities involved in the research and development (R&D) or production of various drug types, including generic and non-generic medications, as well as veterinary drugs. According to Technavio's market analysis, the global pharmaceuticals market size is determined by the consolidated revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of this market include the increasing global population aging, with the number of individuals over 60 years old in the US and Europe predicted to reach nearly one-quarter and similar population ratios, respectively, by 2050 and 2030, respectively. - The Motion Sickness Drugs Market is experiencing significant growth, fueled by the Availability of over-the-counter (OTC) drugs. Businesses are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

• Major Findings:
  • Availability of over-the-counter (OTC) drugs
  • Availability of motion sickness drugs in multiple dosage forms
  • Nonpharmacological countermeasures to treat motion sickness
  • Launch of generics
• Growth Projections

The market size is estimated to grow by USD 139.5 million, at a CAGR of 4.37% during the forecast period. Motion sickness continues to pose a significant challenge for travelers, impairing their ability to journey comfortably. Current treatment methods leave much to be desired, but recent advancements in neuroimaging, neuron physiology, and neuropharmacology offer promising possibilities for the creation of effective anti-motion sickness drugs. Significant strides have been made in comprehending the neurological mechanisms and brain regions linked to motion sickness and its accompanying symptoms, such as nausea. Traditional neurophysiology, pathway mapping, and magnetic resonance imaging (MRI) have been employed to investigate various areas of the brain, including the cortex, cerebellum, and brainstem. These techniques have expanded our knowledge of the environmental and behavioral triggers of motion sickness and the protective factors against it.

For insights on company offerings- Request a sample report!

• Regional Insights

The Motion Sickness Drugs Market represents a significant business opportunity, driven by the increasing prevalence of motion sickness and the demand for effective treatments. Key players in this market include GlaxoSmithKline, Boehringer Ingelheim, and Merck. These companies offer various motion sickness drugs, such as scopolamine, dimenhydrinate, and meclizine, to alleviate symptoms. Market growth is expected due to rising travel frequencies and the expanding tourism industry. However, potential side effects and regulatory challenges pose challenges for market expansion.

About Technavio                                                                        

Technavio is a global market research company offering comprehensive reports and insights on various industries. Our research helps businesses make informed decisions by providing actionable data and trends. Technavio is based on four simple principles: easy-to-access reports, robust industry coverage, a focus on new and emerging technologies, and competitive pricing. We believe in helping companies and executives become better equipped to make faster, sounder, and more effective decisions. Technavio is one of the most influential market research and advisory firms in the world. We work with business and technology leaders to provide cutting-edge market research and insights to companies. 

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/